STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC

An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma

(2016) Hasita Horlad et al.   CANCER SCIENCE

Combinatorial immunotherapy strategies for hepatocellular carcinoma

(2016) Maria Tagliamonte et al.   CURRENT OPINION IN IMMUNOLOGY

Tissue-resident and memory properties of human T-cell and NK-cell subsets

(2016) Enrico Lugli et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

(2016) Frank A. Schildberg et al.   IMMUNITY

The cancer vaccine resurgence

(2016) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Targeting transcription factor STAT3 for cancer prevention and therapy

(2016) Edna Zhi Pei Chai et al.   PHARMACOLOGY & THERAPEUTICS

Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?

(2016) Robert O. Dillman   Human Vaccines & Immunotherapeutics

Multiple-purpose immunotherapy for cancer

(2015) V.I. Seledtsov et al.   BIOMEDICINE & PHARMACOTHERAPY

Measles virus hemagglutinin triggers intracellular signaling in CD150-expressing dendritic cells and inhibits immune response

(2015) Olga Romanets-Korbut et al.   Cellular & Molecular Immunology

Intratumoral dendritic cells in the anti-tumor immune response

(2015) Yang Liu et al.   Cellular & Molecular Immunology

The impact of dendritic cell–tumor fusion cells on cancer vaccines - past progress and future strategies

(2015) Mikio Kajihara et al.   Immunotherapy

Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model

(2015) Lina Chakrabarti et al.   PLoS One

A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts

(2015) Meihua Chen et al.   Scientific Reports

Hepatocellular carcinoma: systemic therapies and future perspectives

(2014) Sameh Mikhail et al.   Expert Review of Anticancer Therapy

NK Cells Are the Crucial Antitumor Mediators When STAT3-Mediated Immunosuppression Is Blocked in Hepatocellular Carcinoma

(2014) Qiangjun Sui et al.   JOURNAL OF IMMUNOLOGY

Immune Profiling of BALB/C and C57BL/6 Mice Reveals a Correlation BetweenUreaplasma parvum-Induced Fetal Inflammatory Response Syndrome-Like Pathology and Increased Placental Expression of TLR2 and CD14

(2013) Ayman B. Allam et al.   AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

(2013) Aurélien Marabelle et al.   JOURNAL OF CLINICAL INVESTIGATION

Challenges in cancer vaccine development for hepatocellular carcinoma

(2013) Luigi Buonaguro et al.   JOURNAL OF HEPATOLOGY

Immune alterations induced by chronic noise exposure: Comparison with restraint stress in BALB/c and C57Bl/6 mice

(2013) Cecilia G. Pascuan et al.   Journal of Immunotoxicology

Targeting Blockage of STAT3 in Hepatocellular Carcinoma Cells Augments NK Cell Functions via Reverse Hepatocellular Carcinoma-Induced Immune Suppression

(2013) X. Sun et al.   MOLECULAR CANCER THERAPEUTICS

A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

(2012) Tim F Greten et al.   BMC CANCER

Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma

(2012) FUJIMASA TADA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Enhancement of Cancer Vaccine Therapy by Systemic Delivery of a Tumor-Targeting Salmonella-Based STAT3 shRNA Suppresses the Growth of Established Melanoma Tumors

(2011) E. R. Manuel et al.   CANCER RESEARCH

NF-κB and STAT3 – key players in liver inflammation and cancer

(2010) Guobin He et al.   CELL RESEARCH

Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma

(2009) Mayer Fishman et al.   JOURNAL OF IMMUNOTHERAPY

Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status

(2009) Nitin Saini et al.   LIVER INTERNATIONAL